controlroom paralax 2

Proven outcomes1,2,3
Superior value

iFR is the gold standard among resting indices, backed by patient outcomes, that reduces costs, procedural time and patient discomfort1,2,3 while providing advance guidance with co-registration.

Learn about the latest iFR studies: DEFINE PCI and LAD deferral.

Proven outcomes

DEFINE FLAIR & iFR Swedeheart

The largest physiology clinical outcome studies
More than 4500 patients, 2 prospective randomized controlled trials, published in the prestigious The New England Journal of Medicine. 

Learn more DEFINE FLAIR, iFR Swedeheart.
Consistent patient outcomes using an iFR guided strategy, as with FFR

Consistent patient outcomes using iFR guided strategy, as with FFR

One year outcome results

p <0.001*
Define flair outcome results

iFR Swedeheart
One year outcome results

p = 0.007*
iFR swedeheart outcome results
* p-values are for non-inferiority of an iFR-guided strategy versus an FFR-guided strategy with respect to 1-year MACE rates; pre-specified non-inferiority margins were 3.4% and 3.2% in DEFINE FLAIR and iFR Swedeheart, respectively

0.89 dichotomous cut-point, backed by clinical outcomes data 1,2,4  

Both DEFINE FLAIR and iFR Swedeheart used a dichotomous 0.89 cut-point in their protocols to assess patient outcomes. Physicians can feel confident in simplifying their clinical decision-making strategy.
iFR cut point

Superior value

Reduced costs per patient3

DEFINE FLAIR and iFR Swedeheart found that on average, compared to FFR, iFR resulted in:
Cost reduction icon


cost reduction

Moneybank icon

dollars saved

Less procedural time 1

DEFINE FLAIR found that an iFR-guided strategy resulted in:
Timer icon


reduction in
procedural time
Clock icon

40.5 minutes (iFR arm)
45.0 minutes (FFR arm)


Improved care1,2

The two trials further established that an iFR-guided strategy enables a faster procedure while almost completely eliminating severe patient symptoms compared to an FFR-guided strategy.
Scale icon
DEFINE FLAIR reported a 90% reduction in patient discomfort
Arrow icon
iFR Swedeheart reported that with no hyperemic agent, you can achieve a 95.7% reduction in patient discomfort using an iFR-guided strategy


iFR is recognized in key industry guidelines

  • iFR has been included in both the AUC (ACC Appropriate Use Criteria)5 and NCDR (National Cardiovascular Data Registry).6
  • Only iFR has been designated as “Definitely Beneficial” by SCAI (Society of Cardiac Angiography and Interventions).7
  • Only iFR has received a Class 1A ESC (European Society of Cardiology) guideline.8

LAD deferral is safer with iFR

Proportion with MACE
LAD deferral
Months since randomization
Sen S, Ahmad Y, et al. Journal Am Coll Cardiol 2019

Dr. Sayan Sen, Consultant Cardiologist, Hammersmith Hospital & Imperial College London, discusses details of the LAD sub-study of DEFINE-FLAIR


“In this study, we have clearly demonstrated that it is safe to defer on the basis of iFR. If I see a patient with an LAD lesion, I'm only reassured for medical therapy if the iFR is negative.”

DEFINE-FLAIR LAD Sub-Study Aims video
Study aims
DEFINE-FLAIR LAD sub-study iFR and FFR results video
iFR and FFR results
Value of iFR Co-registration video
Value of iFR and Co-registration

DEFINE PCI: Unseen focal lesions cause residual ischemia

The DEFINE PCI study used iFR pullback to understand the rate and causes of residual ischemia in 500 patients undergoing contemporary PCI. Early results find that residual ischemia is common, and causes are treatable.10
Dr. Allen Jeremias, Director of Interventional Cardiology Research and Associate Director of the Cardiac Catheterization Laboratory, St. Francis Hospital, New York, and principal investigator of DEFINE PCI, discusses the study findings at ACC 2019.
Study findings residual ischemia video

Study findings: Residual ischemia

- Dr. Allen Jeremias

Residual ischemia treatment options video

Can the residual ischemia be treated?

- Dr. Allen Jeremias

Role of physiologic guidance video

Role of physiologic guidance

- Dr. Allen Jeremias



Find out what Drs. Allen Jeremias, Gregg Stone, Habib Samady and Manesh Patel will discuss in the TCTMD roundtable series: Is physiologic guidance the solution to residual ischemia? A closer look at DEFINE PCI.

TCTMD roundtable video



Find out what Drs. Allen Jeremias, Gregg Stone, Habib Samady and Manesh Patel will discuss in the TCTMD roundtable series: Is physiologic guidance the solution to residual ischemia? A closer look at DEFINE PCI.

iFR Co-registration

Decide not just whether to treat,
but where to treat with
iFR Co-registration


Only Philips co-registers iFR values directly onto the angiogram, allowing you to see precisely which parts of the vessel are causing ischemia, and uses virtual stenting to predict treatment results.

Philips is dedicated to the advancement of physiology-guided PCI. Since the introduction of hyperemia-free iFR modality in 2014, iFR has been studied in nearly 15,000 patients and used in >5,000 cath labs around the world.9

iFR adoption worldwide
iFR adoption graph worldwide

Watch the late breaking presentations and summaries for DEFINE FLAIR and iFR Swedeheart

Omniwire image

OmniWire: the world’s first solid core pressure wire


With an all new workhorse design only OmniWire combines confidence in wire performance with proven iFR outcomes1,2,3 and iFR Co-registration, making it easy to benefit from physiology throughout the case.

1. Davies JE, et al., Use of the Instantaneous Wave-free Ratio or Fractional Flow Reserve in PCI. N Engl J Med. 2017 May 11;376(19):1824-1834.

2. Gotberg M, et al., iFR-SWEDEHEART Investigators.. Instantaneous Wave-free Ratio versus Fractional Flow Reserve to Guide PCI. N Engl J Med. 2017 May 11;376(19):1813-18233.

3. Patel M. “Cost-effectiveness of instantaneous wave-Free Ratio (iFR) compared with Fractional Flow Reserve (FFR) to guide coronary revascularization decisionmaking.” Late-breaking Clinical Trial presentation at ACC on March 10, 2018.

4. An iFR cut-point of 0.89 matches best with an FFR ischemic cut-point of 0.80 with a specificity of 87.8% and sensitivity of 73.0%. (From ADVISE II and iFR Operator's Manual 505-0101.23)

5. Patel M, et al., ACC/AATS/AHA/ASE/ASNC/SCAI/SCCT/STS 2017 Appropriate Use Criteria for Coronary Revascularization in Patients with Stable Ischemic Heart Disease. J Am Coll Cardiol. 2017 May 2;69(17):2212-2241.

6. ACC CathPCI Hospital Registry.

7. Lofti A, et al. Focused update of expert consensus statement: Use of invasive assessments of coronary physiology and structure: A position statement of the society of cardiac angiography and interventions. Catheter Cardiovasc Interv. 2018;1–12.

8. 2018 ESC/EACTS Guidelines on myocardial revascularization: The task force on myocardial revascularization of the European society of cardiology (ESC) and European association for cardio-thoracic surgery (EACTS). Eur Heart J. 2018;00:1-96.

9. A third party Philips internal sales data report (Oracle) on file.

10. Jeremias A et al., Blinded Physiological Assessment of Residual Ischemia After Successful Angiographic Percutaneous Coronary Intervention: The DEFINE PCI Study. JACC Cardiovasc Interv. 2019 Oct 28;12(20):1991-2001.

Our site can best be viewed with the latest version of Microsoft Edge, Google Chrome or Firefox.